The Nationwide Institute for Well being and Care Excellence (NICE) has reaffirmed its stance in opposition to recommending Alzheimer’s therapies donanemab and lecanemab for NHS use, citing inadequate cost-effectiveness.
Regardless of extra proof submitted by producers, the impartial appraisal committee concluded that the therapies don’t present sufficient profit to justify their important price.
NICE first raised considerations about these therapies final yr, figuring out that their medical advantages didn’t outweigh the monetary burden they’d place on the NHS.
Learn Subsequent: Denali Therapeutics Ends ALS Trial Extension, Analyst Stays Optimistic Regardless of Trial Setback
Though the U.Okay.’s Medicines and Healthcare Merchandise Regulatory Company (MHRA) authorised Eli Lilly’s Kisunla (donanemab) in October, NICE refused to cowl it.
The company dominated that the price of offering donanemab balanced in opposition to the comparatively small profit can not at present be thought-about good worth for the taxpayer.
In August, MHRA authorised Biogen Inc’s BIIB Leqembi (lecanemab).
Regardless of the approval, NICE stated in its steering draft,” advantages of the brand new Alzheimer’s drug lecanemab are too small to justify the prices.”
Following a request for additional knowledge, the newest evaluation has bolstered that donanemab and lecanemab stay economically unviable for NHS funding.
“Price and proof gaps stay limitations to approving funding within the NHS for donanemab and lecanemab,” the company says in its assertion.
Stakeholders are inspired to contribute their views earlier than the session interval closes on March 27, 2025.
A 3rd committee assembly will assessment all responses and extra analyses earlier than NICE points its last suggestions.
Worth Motion: On the final examine on Thursday, BIIB inventory was up 1.50% at $145.92, and LLY inventory was down 2.82% at $903.84.
Learn Subsequent:
Picture through Shutterstock
Market Information and Information delivered to you by Benzinga APIs
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
